Role of N-terminal pro-B-type natriuretic peptide in risk stratification in patients presenting in the emergency room

Clinical Chemistry

Volumn 51, Issue 9, 2005, Pages 1624-1631

  Möckel, Martin ^a   Müller, Reinhold ^b   Vollert, Jörn O ^a   Müller, Christian ^a   Carl, Angelika ^c   Peetz, Dirk ^d   Post, Felix ^e   Kohse, J Klaus ^c   Lackner, Karl J ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b JAMES COOK UNIVERSITY   (Australia)

^c KLINIKUM OLDENBURG   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e Johannes G   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO B TYPE NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; HEMOGLOBIN; TROPONIN T; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DEATH; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; EMERGENCY WARD; FEMALE; FOLLOW UP; HEART DISEASE; HEART FAILURE; HIGH RISK POPULATION; HUMAN; INTENSIVE CARE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PROGNOSIS; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; UNIVERSITY HOSPITAL;

ACUTE DISEASE; AGE FACTORS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHRONIC DISEASE; CREATININE; EMERGENCY MEDICAL SERVICES; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE, CONGESTIVE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; RISK ASSESSMENT; TROPONIN T;

EID: 24144503707     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.049155     Document Type: Article

References (35)

1. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldmanmd AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001;104:2996-3007.
2. Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 2004;90:297-303.
3. Lindahl B, Lindback J, Jernberg T, Johnston N, Stridsberg M, Venge P, et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during Instability in coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol 2005;45:533-41.
4. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-Terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-75.
5. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E, Lopez L, Cotes C, Bellido J, et al. N-Terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 2004; 6:301-8.
6. Bayes-Genis A, Bellido-Casado J, Zapico E, Cotes C, Belda J, Lopez L, et al. N-Terminal pro-brain natriuretic peptide reflects pulmonary capillary leakage in patients with acute dyspnea. Am J Cardiol 2004;94:669-70.
7. Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, Clerico A. Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin Chem Lab Med 2004;42:37-44.
8. Reinsch C. Smoothing by spline functions. Numerische Mathematik 1967;10:177-83.
9. Schimek MG. Smoothing and regression. New York: John Wiley and Sons, 2000:1-16.
10. Crichton NJ, Hinde JP, Marchini J. Models for diagnosing chest pain: is CART helpful? Stat Med 1997;16:717-27.
11. Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997;30:1428-36.
12. Breiman L, Friedman JOR, Stone C. Classification and regression trees. New York: Chapman and Hall, 1984:203-15.
13. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-85.
14. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Due P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347: 161-7.
15. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-54.
16. Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003;41:2010-7.
17. McCullough PA, Hollander JE, Nowak RM, Storrow AB, Duc P, Omland T, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med 2003;10:198-204.
18. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002;106: 416-22.
19. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003;41:113-20.
20. Yap LB, Ashrafian H, Mukerjee D, Coghlan JG, Timms PM. The natriuretic peptides and their role in disorders of right heart dysfunction and pulmonary hypertension. Clin Biochem 2004;37: 847-56.
21. Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG. Natriuretic peptides, respiratory disease, and the right heart. Chest 2004;126:1330-6.
22. Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004;43: 764-70.
23. Leuchte HH, Neurohr C, Baumgartner R, Holzapfel M, Giehrl W, Vogeser M, et alJ. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004;170:360-5.
24. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-70.
25. Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003;89:745-51.
26. Luchner A, Hengstenberg C, Lowel H, Trawinski J, Baumann M, Riegger GAJ, et al. N-Terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function. Hypertension 2002;39:99-104.
27. Januzzi J, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-54.
28. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004;50:33-50.
29. Maisel A, Hollander JE, Guss D, McCullough P, Nowak R, Green G, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): a multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 2004;44:1328-33.
30. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004;164:1978-84.
31. Jernberg T, James S, Lindahl B, Stridsberg M, Venge P, Wallentin L. NT-proBNP in unstable coronary artery disease-experiences from the FAST, GUSTO IV and FRISC II trials. Eur J Heart Fail 2004;6:319-25.
32. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002;40:437-45.
33. Zeller M, Cottin Y, Laurent Y, Danchin N, L'Huillier I, Collin B, et al. N-Terminal pro-brain natriuretic peptide levels in patients with non-ST-elevation myocardial infarction. Cardiology 2004;102:37-40.
34. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, et al. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail 2004;6:343-50.
35. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.